| Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium IG McKeith, BF Boeve, DW Dickson, G Halliday, JP Taylor, D Weintraub, ... Neurology 89 (1), 88-100, 2017 | 3764 | 2017 |
| Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease OMA El‐Agnaf, SA Salem, KE Paleologou, MD Curran, MJ Gibson, ... The FASEB journal 20 (3), 419-425, 2006 | 799 | 2006 |
| Protein aggregation in the brain: the molecular basis for Alzheimer’s and Parkinson’s diseases GB Irvine, OM El-Agnaf, GM Shankar, DM Walsh Molecular medicine 14, 451-464, 2008 | 725 | 2008 |
| α‐Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma OMA El-Agnaf, SA Salem, KE Paleologou, LJ Cooper, NJ Fullwood, ... The FASEB Journal 17 (13), 1-16, 2003 | 703 | 2003 |
| α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer B Fauvet, MK Mbefo, MB Fares, C Desobry, S Michael, MT Ardah, E Tsika, ... Journal of Biological Chemistry 287 (19), 15345-15364, 2012 | 674 | 2012 |
| Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease T Tokuda, MM Qureshi, MT Ardah, S Varghese, SAS Shehab, T Kasai, ... Neurology 75 (20), 1766-1770, 2010 | 594 | 2010 |
| CSF and blood biomarkers for Parkinson's disease L Parnetti, L Gaetani, P Eusebi, S Paciotti, O Hansson, O El-Agnaf, ... The Lancet Neurology 18 (6), 573-586, 2019 | 550 | 2019 |
| Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease T Tokuda, SA Salem, D Allsop, T Mizuno, M Nakagawa, MM Qureshi, ... Biochemical and biophysical research communications 349 (1), 162-166, 2006 | 511 | 2006 |
| Aggregates from mutant and wild-type α-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β-sheet and amyloid-like … OMA El-Agnaf, R Jakes, MD Curran, D Middleton, R Ingenito, E Bianchi, ... FEBS letters 440 (1-2), 71-75, 1998 | 498 | 1998 |
| Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration B Mollenhauer, V Cullen, I Kahn, B Krastins, TF Outeiro, I Pepivani, J Ng, ... Experimental neurology 213 (2), 315-325, 2008 | 452 | 2008 |
| Certain inhibitors of synthetic amyloid β-peptide (Aβ) fibrillogenesis block oligomerization of natural Aβ and thereby rescue long-term potentiation DM Walsh, M Townsend, MB Podlisny, GM Shankar, JV Fadeeva, ... Journal of Neuroscience 25 (10), 2455-2462, 2005 | 406 | 2005 |
| Court JA, Schlossmacher MG, Allsop D. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease OM El-Agnaf, SA Salem, KE Paleologou, MD Curran, MJ Gibson Faseb j 20 (3), 419-425, 2006 | 384 | 2006 |
| Formation of hydrogen peroxide and hydroxyl radicals from Aβ and α-synuclein as a possible mechanism of cell death in Alzheimer’s disease and Parkinson’s disease BJ Tabner, S Turnbull, OMA El-Agnaf, D Allsop Free Radical Biology and Medicine 32 (11), 1076-1083, 2002 | 355 | 2002 |
| Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of α-synuclein protein implicated in Parkinson's disease OMA El-Agnaf, R Jakes, MD Curran, A Wallace FEBS letters 440 (1-2), 67-70, 1998 | 352 | 1998 |
| Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia BJ Tabner, OMA El-Agnaf, S Turnbull, MJ German, KE Paleologou, ... Journal of Biological Chemistry 280 (43), 35789-35792, 2005 | 298 | 2005 |
| Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease NK Majbour, NN Vaikath, KD Van Dijk, MT Ardah, S Varghese, ... Molecular neurodegeneration 11, 1-15, 2016 | 274 | 2016 |
| Oligomerization and toxicity of β-amyloid-42 implicated in Alzheimer's disease OMA El-Agnaf, DS Mahil, BP Patel, BM Austen Biochemical and biophysical research communications 273 (3), 1003-1007, 2000 | 271 | 2000 |
| Cerebrospinal fluid lysosomal enzymes and alpha‐synuclein in Parkinson's disease L Parnetti, D Chiasserini, E Persichetti, P Eusebi, S Varghese, ... Movement Disorders 29 (8), 1019-1027, 2014 | 267 | 2014 |
| Detection of elevated levels of soluble α-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies KE Paleologou, CL Kragh, DMA Mann, SA Salem, R Al-Shami, D Allsop, ... Brain 132 (4), 1093-1101, 2009 | 259 | 2009 |
| Cerebrospinal fluid biomarkers in Parkinson disease L Parnetti, A Castrioto, D Chiasserini, E Persichetti, N Tambasco, ... Nature Reviews Neurology 9 (3), 131-140, 2013 | 258 | 2013 |
Nour MajbourMRC Prion Unit at UCLVerified email at ucl.ac.uk